Navidea Biopharmaceuticals EBIT 2010-2023 | NAVB

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Navidea Biopharmaceuticals ebit from 2010 to 2023. Ebit can be defined as earnings before interest and taxes.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Revenue Gross Profit Operating Income EBITDA Net Income Shares Outstanding

Navidea Biopharmaceuticals ebit from 2010 to 2023. Ebit can be defined as earnings before interest and taxes.

Related Stocks
Company Name	Market Cap
Intuitive Surgical (ISRG)	$183.2B
Thermo Fisher Scientific (TMO)	$161.4B
Edwards Lifesciences (EW)	$44.8B
Alcon (ALC)	$43.7B
IDEXX Laboratories (IDXX)	$42.8B
DexCom (DXCM)	$33.4B
IQVIA Holdings (IQV)	$32.4B
Mettler-Toledo (MTD)	$25.3B
STERIS (STE)	$22B
SONOVA HOLDING (SONVY)	$17.4B
Waters (WAT)	$17.1B
Hologic (HOLX)	$14.6B
Sysmex ADR (SSMXY)	$10.2B
Penumbra (PEN)	$9B
Masimo (MASI)	$8.6B
Globus Medical (GMED)	$7.2B
Glaukos (GKOS)	$5.5B
Teleflex (TFX)	$5.1B
Integer Holdings (ITGR)	$4B
TransMedics (TMDX)	$3.6B
PROCEPT BioRobotics (PRCT)	$3.3B
LivaNova (LIVN)	$2.4B
Nihon Kohden (NHNKY)	$2.1B
Elekta AB (EKTAY)	$1.9B
Veracyte (VCYT)	$1.8B
Alphatec Holdings (ATEC)	$1.6B
Artivion (AORT)	$1.3B
Paragon 28 (FNA)	$1.1B
OPKO Health (OPK)	$1.1B
Pulse Biosciences (PLSE)	$1B